The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Jun. 30, 8:39 AM

Slide #3. Dipexium Pharmaceuticals, Inc. Secondary Offering

Company: Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX)
Date announced: 6/24/2015
Shares Offered: 1,480,000
Date of Pricing: 6/25/2015
Price Per Share: $12.50
Secondary Offering Details: Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), today announced it intends to offer and sell common stock in an underwritten public offering. The Company also expects to grant to the underwriters for the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. Raymond James & Associates, Inc. is acting as sole book-running manager for the offering. Feltl and Company is acting as co-manager for the offering. - updated 6/25 - Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), today announced the pricing of an underwritten public offering of 1,480,000 shares of common stock at a public offering price of $12.50 per share. The gross proceeds to Dipexium from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $18.5 million.

Dipexium Pharmaceuticals is a late stage pharmaceutical company focused on the development and commercialization of Locilex™ (pexiganan acetate cream 1%), a novel, broad spectrum, topical antibiotic. Locilex™ is a chemically synthesized, 22-amino acid peptide isolated from the skin of the African Clawed Frog. Its novel mechanism of action kills microbial targets through disruption of bacterial cell membrane permeability. Locilex™ is initially being targeted for the treatment of mild infections of diabetic foot ulcers.
Open the DPRX Page at The Online Investor »

Company Name:  Dipexium Pharmaceuticals Inc
Website:  www.dipexiumpharmaceuticals.com
Sector:  Drugs & Pharmaceuticals
 

Open the DPRX Page at The Online Investor (in a new window) »

June 30, 2015    8:39 AM Eastern
Quotes delayed 20 minutes


Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.